mva-bn-brachyury
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2018 (NCT03493945)
Timeline
Indications
Mechanism of action
- VHL/TBXTImmunity, active
VHL/TBXT immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04020094 | Phase 2 | Nov 30, 2019 | Bavarian Nordic, Genentech, University of Utah |
| NCT04134312 | Phase 1 | Oct 18, 2019 | Bavarian Nordic, National Cancer Institute (NCI) |
| NCT03493945 | Phase 1/Phase 2 (Phase 2) | May 1, 2018 | National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bavarian Nordic | For profit | 2 | 1 | 2 | 2019 |
| National Cancer Institute (NCI) | Government | 2 | 1 | 2 | 2018 |
| Genentech | For profit | 1 | 0 | 1 | 2019 |
| University of Utah | Academic/Hospital | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1